<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2016-07-11 17:00:04Clinical research Food and Drug Administration Pharmaceutical industry Drug safety Savient pharmaceuticals Pharmaceuticals policy Pegloticase Biologic license application PEGylation Validation Pharmacovigilance Clinical trial |
Add to Reading List |
Microsoft Word - Savient Update on KRYSTEXXA BLA Filingdoc | Microsoft Word - Savient Phase 3 Dosing press releasedocDocID: 1ri7E - View Document |
 | Microsoft Word - Savient press release re ACRdocDocID: 1reUR - View Document |
 | Microsoft Word - Savient press release Puricase SPAdocDocID: 1qW9f - View Document |
 | Microsoft Word - puricase-Phase I-ivpress release.docDocID: 1qOjy - View Document |
 | Microsoft Word - Savient Reports Positive Top-Line ResultsdocDocID: 1qCIQ - View Document |